Moderna says the FDA will consider its new flu shot after resolving a public dispute

The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute ...

FDA plans review of Moderna flu vaccine for older adults

Moderna's mRNA-1010 flu vaccine for older adults could be made available by the end of 2026, the pharmaceutical company announced on Friday.

RNA Analysis Market Size Worth USD 23.39 Billion by 2035 Fueled by Expansion of RNA Therapeutics and Precision Medicine

According to Precedence Research, the global RNA analysis market size is expected to be worth USD 23.39 billion by 2035, increasing from USD 10.21 billion in 2026, with a strong CAGR of 9.65% from ...
The New York Times

New Variant Raises Concerns of Another Bad Flu Season

Here’s what to know about the dominant version of the virus that’s circulating now. By Dani Blum The flu constantly morphs and mutates. Often, it surprises researchers a little. This year, the virus ...
Frontiers

Comparative plasma metabolomics of Delta and Omicron SARS-CoV-2 variants: insights into variant-specific pathogenesis and therapeutic implications

Background: The emergence of SARS-CoV-2 led to a global pandemic. Delta and Omicron, classified as concerning variants, differ significantly in transmissibility, disease severity, and antibody ...
Argus Leader

Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...
The News Leader

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...